B of A Securities maintains Neutral on Hims & Hers Health, raises target to $37

B of A Securities analyst Allen Lutz has maintained a Neutral rating on Hims & Hers Health while raising the price target to $37 from the previous $36. The revised target indicates a modest adjustment in the valuation outlook for the company, which is listed on the NYSE under the ticker HIMS.

The decision to hold the rating at Neutral suggests that the firm sees the stock's risk-reward profile as balanced at the new price level. While the increased target acknowledges potential upside, the stance implies that the stock may not offer a significant edge compared to other opportunities in the sector at this time.

Rating and Price Target Details

The following table outlines the revised ratings and price targets set by B of A Securities:

Metric	Value
Rating	Neutral
Previous Price Target	$36
New Price Target	$37
Exchange	NYSE
Ticker Symbol	HIMS

Hims & Hers Health operates as a telehealth platform, providing access to various health and wellness products. The company's performance is closely watched by investors tracking the digital health sector.

Hims & Hers Health has outperformed the market over the past 5 years by 17.4% on an annualized basis, producing an average annual return of 28.89%. This performance highlights the impact of compounded returns on investor wealth over time. The company currently commands a market capitalization of $8.66 billion.

Investment Growth Analysis

The significant appreciation in stock price translates to substantial growth for initial investors. If an individual had purchased $100 worth of Hims & Hers Health stock 5 years ago, that investment would be valued at $355.78 today. This calculation is based on a current share price of $37.41.